This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Reasons Why Investors Should Buy Merck (MRK) Stock Now
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and a solid pipeline are some key reasons to own Merck's (MRK) stock.
AstraZeneca (AZN) Drugs Get CHMP Recommendation for Breast Cancer
by Zacks Equity Research
The EMA's Committee for Medicinal Products for Human Use recommends granting marketing approval to AstraZeneca's (AZN) cancer drugs, Enhertu and Lynparza, for treating certain patients with breast cancer.
The Zacks Analyst Blog Highlights UnitedHealth, Chevron, AstraZeneca, SAP and Bayer ktiengesellschaftt
by Zacks Equity Research
UnitedHealth, Chevron, AstraZeneca, SAP and Bayer ktiengesellschaftt are part of Zacks top Analyst Blog.
Top Analyst Reports for UnitedHealth, Chevron & AstraZeneca
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Chevron Corporation (CVX), and AstraZeneca PLC (AZN).
Astrazeneca (AZN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $63.55, marking a +1.15% move from the previous day.
Ionis (IONS), AstraZeneca's Amyloidosis Drug Meets Study Goals
by Zacks Equity Research
Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Mereo BioPharma (MREO) Up as AstraZeneca Reportedly Eyes Buyout
by Zacks Equity Research
Shares of Mereo BioPharma (MREO) surge after reports suggest that AstraZeneca (AZN) is interested in acquiring it.
Valneva (VALN) Stock Declines 59% in 3 Months: Here's Why
by Zacks Equity Research
Though Valneva's (VALN) COVID-19 vaccine looks promising, the European Commission's intent to terminate the advance purchase agreement for the vaccine puts the future of the company's COVID-19 vaccine program into jeopardy.
Astrazeneca (AZN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $60.86, moving +0.48% from the previous trading session.
Astrazeneca (AZN) Stock Moves -1.45%: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $61.79, marking a -1.45% move from the previous day.
Emergent (EBS) Stock Down as J&J Ends COVID-19 CDMO Contract
by Zacks Equity Research
Emergent (EBS) sends contract breach notice to J&J, following the latter's decision to end their contract for CDMO services for its COVID-19 vaccine. J&J also cites contract breach as the basis for termination.
AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death to Half
by Zacks Equity Research
Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer patients.
Apellis (APLS) Files NDA for Pegcetacoplan in Geographic Atrophy
by Zacks Equity Research
Apellis (APLS) submits a new drug application to the FDA for pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.
The Zacks Analyst Blog Highlights AstraZeneca, Merck, Roche, J&J, and Pfizer
by Zacks Equity Research
AstraZeneca, Merck, Roche, J&J, and Pfizer are part of Zacks top Analyst Blog
Pharma Stock Roundup: EU Nod for AZN, JNJ & Others, PFE COVID Jab Effective in Kids
by Kinjel Shah
European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.
Top Research Reports for Johnson & Johnson, Walt Disney & NextEra Energy
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), The Walt Disney Company (DIS) and NextEra Energy, Inc. (NEE).
AstraZeneca (AZN) Gets EU Nod for COVID-19 Booster Shot
by Zacks Equity Research
AstraZeneca's (AZN) third/booster dose of its COVID-19 vaccine gets authorized in Europe for use in adults, both for homologous and heterologous use.
Pharma Stock Roundup: FDA Nod to PFE COVID Jab for Age 5-11 & LLY's Tirzepatide
by Kinjel Shah
FDA grants emergency approval to Pfizer's COVID-19 vaccine for use in children 5- to 11-year old and approves Lilly's (LLY) novel diabetes treatment, Mounjaro (tirzepatide).
Merck (MRK) Outperforms Industry This Year So Far: Here's Why
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.
AstraZeneca (AZN) Inks Deal to Develop COVID-19 Antibodies
by Zacks Equity Research
AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.
Valneva (VALN) Down as EU Considers Ending COVID-Vaccine Deal
by Zacks Equity Research
Per the agreement with the European Commission, Valneva (VALN) has 30 days from May 13, 2022 to win a marketing authorization in the EU for its COVID vaccine or offer an acceptable remediation plan.
Ironwood (IRWD) Q1 Earnings Miss, Linzess Growth Continues
by Zacks Equity Research
Ironwood (IRWD) witnesses strong year-over-year sales growth on continued demand for Linzess. Its first-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines.
Apellis (APLS) Hit By Wider-Than-Expected Q1 Loss, Revenues Top
by Zacks Equity Research
Apellis' (APLS) earnings missed estimates in the first quarter of 2022, while revenues surpassed expectations.
Ionis (IONS) Q1 Earnings & Sales Beat Estimates, Stock Rises
by Zacks Equity Research
Ionis (IONS) incurs a narrower-than-expected loss in Q1. Its sales also come ahead of estimates. Stock moves up in response to the results.
Moderna (MRNA) Beats on Q1 Earnings, to Start Two Late Studies
by Zacks Equity Research
Moderna's (MRNA) Spikevax sales beat expectations. The company plans to start late-stage studies for Omicron-containing bivalent booster and seasonal flu vaccines later this year. Stock gains in pre-market.